7/10/2013 8:13:45 AM
Get the latest biotech news where you want it. Sign up for the free
GenePool newsletter today!
Myriad Genetics Inc., a provider of tests for breast cancer risk, filed a lawsuit today to shut a competitor that set up shop last month after a mixed U.S. Supreme Court ruling on patents for genetic material. Ambry Genetics, a closely held company in Aliso Viejo, California, announced June 13 it would offer the breast cancer tests hours after a high court ruling that invalidated some of Myriad’s patent claims on genes linked to breast and ovarian cancer. Myriad said the Ambry tests infringe 10 other patents it owns or licenses on the testing process that weren’t part of that Supreme Court case. The other owners of the patents, comprising the University of Utah and University of Pennsylvania, Ontario’s Hospital for Sick Children and Endorecherche Inc., also joined in the suit against Ambry.
Help employers find you! Check out all the jobs and post your resume.
comments powered by